|
Hypertensive disease
|
|
0.040 |
GeneticVariation
|
BEFREE |
However, HSD3B1 T→C Leu338, HTR2A T102C, GNAS T393C, and RGS2 G638A polymorphisms were not associated with hypertension risk.
|
23859711 |
2013 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Moreover, multivariable Cox regression analysis including tumor stage and melanoma subtype proved the T393C polymorphism to be an independent factor for metastasis (p = 0.012).-
|
21156401 |
2010 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers.
|
20027678 |
2009 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer.
|
19274060 |
2009 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our results show that besides tumor stage, lymph node status, and tumor grade, the GNAS1 T393C status is a novel independent host factor for disease progression in patients with clear cell renal cell carcinoma and provides further evidence for the T393C polymorphism as a general prognostic tumor marker.
|
16467086 |
2006 |
|
Hypertensive disease
|
|
0.040 |
GeneticVariation
|
BEFREE |
These results did not support the hypothesis that the interaction between the T393C polymorphism and GGT in the association with hypertension could be caused by an indirect effect of Gs proteins mediated by glucose metabolism.
|
15894831 |
2004 |
|
Hypertensive disease
|
|
0.040 |
GeneticVariation
|
BEFREE |
Because alcohol consumption is known to affect blood pressure partly through the beta-AR-Gs protein system, we examined the possible interaction between GNAS1 T393C polymorphism and drinking status in the association with hypertension in the present study.
|
12862199 |
2003 |
|
Hypertensive disease
|
|
0.040 |
GeneticVariation
|
BEFREE |
Because hypertension is considered to be a complex disorder resulting from interactions between genetic and environmental factors, we further analyzed the T393C polymorphism, with consideration of interactions between the polymorphism and confounding factors in regression models.
|
12215464 |
2002 |
|
Malignant neoplasm of esophagus
|
|
0.030 |
GeneticVariation
|
BEFREE |
The aim of the present study was to determine if the single-nucleotide polymorphism GNAS T393C can be used for treatment stratification in esophageal cancer patients.
|
24986238 |
2014 |
|
Esophageal carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The aim of the present study was to determine if the single-nucleotide polymorphism GNAS T393C can be used for treatment stratification in esophageal cancer patients.
|
24986238 |
2014 |
|
Esophageal Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The aim of the present study was to determine if the single-nucleotide polymorphism GNAS T393C can be used for treatment stratification in esophageal cancer patients.
|
24986238 |
2014 |
|
Esophageal carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Determination of T393C-SNP preoperatively will allow allocation of EC patients into different risk profiles which may help to stratify patients eligible for neoadjuvant and or adjuvant therapy.
|
21340746 |
2011 |
|
Esophageal Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Determination of T393C-SNP preoperatively will allow allocation of EC patients into different risk profiles which may help to stratify patients eligible for neoadjuvant and or adjuvant therapy.
|
21340746 |
2011 |
|
Malignant neoplasm of esophagus
|
|
0.030 |
GeneticVariation
|
BEFREE |
Determination of T393C-SNP preoperatively will allow allocation of EC patients into different risk profiles which may help to stratify patients eligible for neoadjuvant and or adjuvant therapy.
|
21340746 |
2011 |
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy.
|
21156401 |
2010 |
|
Esophageal Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer.
|
19274060 |
2009 |
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers.
|
20027678 |
2009 |
|
Malignant neoplasm of esophagus
|
|
0.030 |
GeneticVariation
|
BEFREE |
The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer.
|
19274060 |
2009 |
|
Esophageal carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The results support the role of the T393C polymorphism as a predictive molecular marker for tumor response to cisplatin/5-FU-based radiochemotherapy in esophageal cancer.
|
19274060 |
2009 |
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015).
|
16467086 |
2006 |
|
Solid Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
GNAS T393C has been shown to predict the postoperative course in solid tumors and may therefore be useful for treatment stratification.
|
24986238 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Determination of T393C-SNP preoperatively potentially allows allocation of NSCLC patients into different risk profiles and may influence the therapeutic strategy.
|
23201296 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
This study suggests that the TT genotype of the GNAS1 T393C polymorphism could be an independent prognostic marker to predict chemotherapy sensitivity, favorable OS and PFS in advanced NSCLC patients with GP treatment.
|
22371153 |
2012 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results suggest that a T393C SNP could be considered as a genetic marker implicated in the pathogenesis of RCC.
|
22931242 |
2012 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, this study did not demonstrate an association between the GNAS T393C genotype and prostate cancer though such a relationship has been described for other cancer entities.
|
21677417 |
2011 |